Navigation Links
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Date:1/3/2012

noclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.

Regeneron Forward-Looking StatementThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of EYLEA and Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize EYLEA and other products and drug candidates, competing drugs that may be superior to EYLEA and Regeneron's products and drug candidates, uncertainty of market acceptance of EYLEA and Regeneron's products and drug candidates, the possibility of EYLEA sales meeting or exceeding any of the cumulative U.S. sales targets triggering payments to Genentech described in this news release, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating th
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
2. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
3. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
4. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
5. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
6. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
7. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
8. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
9. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
10. Regeneron Reports Second Quarter 2011 Financial and Operating Results
11. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013 Although colonoscopy exams prevent many ... most sensitive method for detecting colorectal cancers 2 , ... cases 3 . EndoChoice ® Inc. today unveiled ... improves the accuracy of this procedure and greatly reduces ... be discussing these clinical trial results and featuring the ...
(Date:5/18/2013)... 18, 2013 The Open Paradigm Project, ... Occupy Psychiatry , and leading organizations in ... a social media campaign showcasing video testimonials by ... which focuses on pathology and illness rather than ... American Psychiatric Association,s (APA) rollout of its latest ...
(Date:5/18/2013)... May 18, 2013 Faruqi & Faruqi, ... investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The ... executives violated federal securities laws by issuing materially ... III drug trials for Tivopath (tivozanib) (titled "TIVO-1").  ...
Breaking Medicine Technology:New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2
... 22, 2007 - Medtronic,(NYSE:MDT) today presented new ... reinforcing the existing safety and efficacy,profile of ... from the 100-patient first-in-man ENDEAVOR I,trial and ... ENDEAVOR,II trial demonstrate that Endeavor is associated ...
... Maintained Stability,Significantly Longer than Placebo and had ... Placebo , MARIETTA, Ga. and COLLEGEVILLE, Pa., ... Pharmaceuticals, a division of Wyeth,(NYSE:WYE), and Lundbeck ... investigational treatment for adult patients,diagnosed with schizophrenia, ...
Cached Medicine Technology:Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 2Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing,Sustained Safety and Significant Reductions in Repeat Procedures 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5
(Date:5/18/2013)... Hayden, ID (PRWEB) May 18, 2013 ... needs when it comes to safety and comfort ... these requirements and provides clients with an effective ... System®. This is an integrated, turnkey communications ... of care, while allowing residents independence and privacy. ...
(Date:5/18/2013)... A ground-breaking advance in colonoscopy technology signals ... presented today at Digestive Disease Week (DDW). Additional ... for colonoscopies and exploring safer methods for removing ... a device called a colonoscope to examine the ... a doctor to look for precancerous polyps called ...
(Date:5/18/2013)... City, Utah (PRWEB) May 18, 2013 ... information on insurance agents’ role in Marketplaces ... alternatives to traditional employer sponsored health benefits, is ... contribution and health reimbursement arrangements . ... of Health and Human Services (HHS) recently released ...
(Date:5/18/2013)... New York, New York (PRWEB) May 18, 2013 ... Inc.’s Gynecare pelvic mesh products continue to move forward ... County Superior Court, Bernstein Liebhard LLP reports. According to ... Management Conference in the Ethicon pelvic mesh litigation will ... indicate that 2,755 complaints have been filed in the ...
(Date:5/18/2013)... Springs, FL (PRWEB) May 18, 2013 The ... dedicated to the special places we call home. These are ... on maps. They are the locations where the people are ... first-rate show takes viewers off the highways and shares the ... best of both nations with an American sports and film ...
Breaking Medicine News(10 mins):Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2
... Two new initiatives designed to improve the management of ... EULAR 2008, the Annual Congress of the European League ... RAID disease impact score , The first, a EULAR ... Rheumatoid Arthritis Impact of Disease, (RAID) score, was based ...
... June 13 Birner Dental Management,Services, Inc. (Nasdaq: ... practices,announced its regular quarterly dividend. The Company,s board ... 17 cents per share of common,stock. The dividend ... record,June 27, 2008., Birner Dental Management Services, ...
... rat research shows , , FRIDAY, June 13 (HealthDay News) ... in the morning may help ease some stresses you ... When rats inhaled the aroma of roasted coffee beans, ... produce proteins with healthful antioxidant activity, the researchers reported. ...
... (PAH)chronically high blood pressure in the blood vessels of ... or HN) have a very poor chance of survival ... to new research from the University of Pennsylvania. ... advanced left heart failure but has never been demonstrated ...
... residents of Lower Manhattan, the terrorist attacks of September ... today by the Health Department,s World Trade Center Health ... likely had posttraumatic stress disorder (PTSD) two to three ... Manhattan residents developed PTSD at three times the usual ...
... to Use Valuable Patient Care,Resources in Manner True to ... of Healthcare,workers from Los Angeles and Orange Counties demonstrated ... LLP on Thursday, June 12th to protest the,firm,s anti-union ... Joseph Health System (SJHS), a $3.4 billion dollar corporation,founded ...
Cached Medicine News:Health News:New insight into RA patient priorities and motivators for clinical trial involvement 2Health News:New insight into RA patient priorities and motivators for clinical trial involvement 3Health News:Coffee Beans May Be Newest Stress-Buster 2Health News:Coffee Beans May Be Newest Stress-Buster 3Health News:Serum sodium predicts mortality 10 times higher in PAH patients 2Health News:1 in 8 Lower Manhattan residents had signs of PTSD 2 to 3 years after 9/11 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 2Health News:Caregivers Protest Foley & Lardner's Union Busting & Intimidation 3
... market:, ,QuietLife 3 is the ... oxygen concentrator for home health and ... attractive, lightweight (26 kg) cabinet, this ... the requirements of the sound-sensitive, energy-conscious ...
... AirSep's new QuietLife 5 Oxygen Concentrator is ... that delivers continuous flow oxygen for prescriptions ... ,As the quietest running concentrator at ... sound-sensitive patients or caregivers. Concentrators are also ...
... NewLife Elite is AirSep Corporations most economical ... to 5 lpm of therapeutic oxygen in ... of thousands of units in daily use ... concentrator is known for high performance, easy ...
OCD-3000 pnuematic conserving regulator....
Medicine Products: